These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 35054306)

  • 21. The 3849 + 10 kB C-->T mutation in a 21-year-old patient with cystic fibrosis.
    Kaplan DM; Niv A; Aviram M; Parvari R; Leiberman A; Fliss DM
    Ear Nose Throat J; 1996 Dec; 75(12):793-5. PubMed ID: 8991230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.
    Fenaux H; Gueneau R; Chaghouri A; Henry B; Mouna L; Roque-Afonso AM; Vauloup-Fellous C
    BMC Infect Dis; 2021 Dec; 21(1):1223. PubMed ID: 34876033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for Pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications.
    Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
    Respir Res; 2021 Apr; 22(1):132. PubMed ID: 33910573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.
    Winnie GB; Cowan RG
    Pediatr Pulmonol; 1991; 10(2):92-100. PubMed ID: 1903199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exacerbation of Secondary Cold Agglutinin Syndrome in the Setting of SARS-CoV-2.
    Bhagat YV; Hussien S; Queenan H; Michael MB
    Cureus; 2021 Nov; 13(11):e19387. PubMed ID: 34925989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).
    Lee JH; Choi M; Jung Y; Lee SK; Lee CS; Kim J; Kim J; Kim NH; Kim BT; Kim HG
    Biosens Bioelectron; 2021 Jan; 171():112715. PubMed ID: 33099241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
    Dhand R
    J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.
    Lechtzin N; John M; Irizarry R; Merlo C; Diette GB; Boyle MP
    Respiration; 2006; 73(1):27-33. PubMed ID: 16113513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Fomsgaard A; Høiby N; Shand GH; Conrad RS; Galanos C
    Infect Immun; 1988 Sep; 56(9):2270-8. PubMed ID: 3410536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19.
    ;
    Liver Res; 2020 Sep; 4(3):109-117. PubMed ID: 32864178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 and
    Jeican II; Inișca P; Gheban D; Tăbăran F; Aluaș M; Trombitas V; Cristea V; Crivii C; Junie LM; Albu S
    Medicina (Kaunas); 2021 Mar; 57(4):. PubMed ID: 33804963
    [No Abstract]   [Full Text] [Related]  

  • 34. Delayed RT-PCR Time-To-Positivity in an adult with SARS-CoV-2 Infection.
    Bunawan NC; Mokoagow MI; Djojo AY; Wistriany N; Nugroho HM; Harlivasari AD; Diponegoro S
    J Infect Dev Ctries; 2021 Jul; 15(7):913-917. PubMed ID: 34343115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring clinical and microbiological evolution of a cystic fibrosis patient over 26 years: experience of a Brazilian CF Centre.
    da Costa Ferreira Leite C; Folescu TW; de Cássia Firmida M; Cohen RWF; Leão RS; de Freitas FAD; Albano RM; da Costa CH; Marques EA
    BMC Pulm Med; 2017 Jul; 17(1):100. PubMed ID: 28705217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series.
    Hung IF; Cheng VC; Li X; Tam AR; Hung DL; Chiu KH; Yip CC; Cai JP; Ho DT; Wong SC; Leung SS; Chu MY; Tang MO; Chen JH; Poon RW; Fung AY; Zhang RR; Yan EY; Chen LL; Choi CY; Leung KH; Chung TW; Lam SH; Lam TP; Chan JF; Chan KH; Wu TC; Ho PL; Chan JW; Lau CS; To KK; Yuen KY
    Lancet Infect Dis; 2020 Sep; 20(9):1051-1060. PubMed ID: 32539986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 in a Cystic Fibrosis Patient.
    Al Lawati A; Al Balushi A; Al Salimi S
    Oman Med J; 2023 Mar; 38(2):e490. PubMed ID: 37132009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Casirivimab and imdevimab for COVID-19.
    Aust Prescr; 2022 Apr; 45(2):58-59. PubMed ID: 35592369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.